Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management

Jafar Kafaie, MD, PhD


June 24, 2021

Because the proposed pathogenesis of CIDP is that of an immune-mediated condition, appropriate agents include intravenous immunoglobulin (IVIg), plasma exchange, prednisone, azathioprine, methotrexate, mycophenolate, cyclosporine, and cyclophosphamide. High-dose steroids or IVIg could be considered as the initial treatment in patients with CIDP.

Although plasma exchange has been shown to improve outcome in patients with CIDP, it is not always a feasible choice for some patients because it may not be readily available in rural areas. Moreover, both plasma exchange and IVIg are costly treatments. Still, plasma exchange may be particularly beneficial in patients with a relapsing course.

Learn more about medication in CIDP treatment.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.